Price Chart

Executive Summary

Medtronic plc is offering to exchange up to 225,361,295 newly issued shares of MiniMed common stock for outstanding Medtronic ordinary shares at a 7% discount to MiniMed's three-day VWAP, subject to an upper limit of 4.5939 MiniMed shares per Medtronic share. The exchange offer is the primary mechanism for Medtronic's tax-efficient divestiture of its ~89.86% stake in MiniMed, creating an independent diabetes-focused company. The filing also includes MiniMed's financials showing strong 16.6% revenue growth in the latest quarter, driven by international sales and new product launches, though the company remains unprofitable on a GAAP basis.

Key Facts

• Medtronic is offering to exchange up to 225,361,295 newly issued MiniMed shares for outstanding Medtronic ordinary shares.
• The exchange ratio offers a 7% discount to MiniMed's three-day VWAP, subject to an upper limit of 4.5939 MiniMed shares per Medtronic share.
• The exchange offer expires on October 9, 2026, unless extended.
• Medtronic currently owns approximately 89.86% of MiniMed's outstanding shares.
• MiniMed reported net sales of $843 million for the three months ended July 31, 2026, a 16.6% increase year-over-year.
• MiniMed reported a net loss of $317 million for the fiscal year ended April 24, 2026.
• The exchange offer is conditioned on, among other things, the receipt of a tax opinion from Skadden, Arps, Slate, Meagher & Flom LLP.
• If the exchange offer is oversubscribed, Medtronic may accept an additional number of shares up to 2% of outstanding Medtronic ordinary shares.
• Following the exchange offer, Medtronic intends to divest any remaining MiniMed stake through a spin-off, split-off, or debt-for-equity exchange.
• MiniMed's unaudited pro forma net loss per share for fiscal year 2026 was $(1.29).

Financial Impact

Medtronic expects to recognize a pre-tax gain of approximately $1.7 billion on the exchange offer, assuming full subscription and the upper limit is in effect. MiniMed's unaudited pro forma net loss for fiscal year 2026 was $362 million.

Risk Factors

• The exchange offer may not be fully subscribed, leaving Medtronic as a controlling shareholder and limiting MiniMed's independence.
• The upper limit on the exchange ratio could reduce the value received by tendering shareholders.
• MiniMed faces significant operational risks including sole-supplier dependencies, manufacturing scale-up challenges for Simplera CGMs, and ongoing product liability litigation.
• The tax-free treatment of the exchange offer is subject to a legal opinion and could be challenged by the IRS, potentially creating significant tax liabilities.
• A substantial number of MiniMed shares will enter the market, potentially depressing the stock price.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 16 SEC documents filed with EDGAR.

US Market Status

Related Tickers